A Randomised, Double Blind, Placebo Controlled Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-7117 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs MT 7117 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 24 Jul 2017 Status changed from active, no longer recruiting to completed.
- 31 May 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Aug 2017.